Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
The aim of this study was to investigate the clinical efficacy and determine the prognostic value of Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) alone versus EGFR-TKIs plus chemotherapy for the treatment of advanced lung adenocarcinoma with EGFR Exon 19 Deletion(19Del), Ex...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2023-06, Vol.102 (26), p.e34110-e34110 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e34110 |
|---|---|
| container_issue | 26 |
| container_start_page | e34110 |
| container_title | Medicine (Baltimore) |
| container_volume | 102 |
| creator | Zhou, Jinhua Qin, Hongya Miao, Jianlong Liu, Ruijuan Wang, Wei |
| description | The aim of this study was to investigate the clinical efficacy and determine the prognostic value of Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) alone versus EGFR-TKIs plus chemotherapy for the treatment of advanced lung adenocarcinoma with EGFR Exon 19 Deletion(19Del), Exon 21 L858R (L858R) mutation. The demographic and clinical characteristics of 110 newly diagnosed metastatic lung adenocarcinoma patients with the EGFR 19Del, L858R mutation from June 2016 to October 2018 were retrospectively analyzed. Total remission rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and patient 1-year/2-year survival between EGFR-TKIs combined with first-line platinum-containing double-drug chemotherapy (Observation) group and an EGFR-TKIs alone (Control) group were evaluated and analyzed. For lung adenocarcinoma patients with the EGFR 19Del, L858R mutation, the Observation group had a better ORR (81.4% vs 52.2%), mPFS (12.0 vs 9 months), and 2-year survival (72.1% vs 52.2%) than the Control group, and the differences were statistically significant (P < .05), but DCR (95.3% vs 88.1%) and 1-year survival (90.7% vs 83.6%) were not significantly different between the groups (P > .05). For lung adenocarcinoma with the EGFR 19Del mutation, the Observation group showed a better ORR (81.8% vs 54.3%), and mPFS (14.5 vs 11.0 months) than the Control group, and the differences were statistically significant (P < .05), but DCR (95.5% vs 91.4%), 1-year survival (90.9% vs 85.7%), and 2-year survival (72.7% vs 60.0%) were not significantly different (P > .05). For lung adenocarcinoma with the EGFR L858R mutation, the Observation group showed a better ORR (81.0% vs 50.0%), mPFS (12.0 vs 9.0 months), and 2-year survival (71.4% vs 43.8%) than the Control group (P < .05), but DCR (95.2% vs 84.4%) and 1-year survival (90.5% vs 81.3%) were not significantly different (P > .05). Compared to EGFR-TKIs alone, EGFR-TKIs combined with chemotherapy improved ORR and mPFS in cases of advanced lung adenocarcinoma with EGFR 19Del, L858R mutation. In particular, patients with the EGFR L858R mutation showed a long-term survival benefit trend. EGFR-TKIs combined chemotherapy may therefore be a viable treatment method for delaying targeted drug resistance. |
| doi_str_mv | 10.1097/MD.0000000000034110 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10313250</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2832576927</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4011-1f35ef0a2c86c12127fa8660219cdbaed254629ae35f92de13ad02c5097df6d13</originalsourceid><addsrcrecordid>eNpdUttuEzEQXSEQDYUvQEJ-5IEtvuwl5gVVTVoqUiFV5dly7NmswWsH25uQr-SXcJJSCn4Zz_GZM0eeKYrXBJ8RzNv3N7Mz_PewihD8pJiQmjVlzZvqaTHBmNZly9vqpHgR4zeMCWtp9bw4YS3jmLZ8Uvyad51RUu2QX0YIG5mMd0g6jdbBr5yPJuZM2t3-4js0v7q8Le8-X2fUegdoAyGO8RG8tjlVPQw-9RDkeodM1tMb6RRoZEe3yhk4r2RQxvlBoq1J_UEAzX_m3oSjGVjY-3h3RChBi2k9vUXDmA7-PqBz1JuYfMjWLVK-9yGhmEa9e1k866SN8Oo-nhZfL-d3F5_KxZer64vzRakqTEhJOlZDhyVV00YRSmjbyWnTYEq40ksJmtZVQ7kEVnecaiBMakxVnf9dd40m7LT4eNRdj8sBtAKXgrRiHcwgw054acS_L870YuU3gmBGGK1xVnh7rxD8jxFiEoOJCqyVDvwYBZ1mWttw2mYqO1JV8DEG6B76ECz2uyBuZuL_XchVbx5bfKj5M_xMqI6Erbcpz_G7HbcQRA_Spv6gV7eclhRThhuGcblHCPsN3fPBEA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2832576927</pqid></control><display><type>article</type><title>Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Zhou, Jinhua ; Qin, Hongya ; Miao, Jianlong ; Liu, Ruijuan ; Wang, Wei</creator><creatorcontrib>Zhou, Jinhua ; Qin, Hongya ; Miao, Jianlong ; Liu, Ruijuan ; Wang, Wei</creatorcontrib><description>The aim of this study was to investigate the clinical efficacy and determine the prognostic value of Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) alone versus EGFR-TKIs plus chemotherapy for the treatment of advanced lung adenocarcinoma with EGFR Exon 19 Deletion(19Del), Exon 21 L858R (L858R) mutation. The demographic and clinical characteristics of 110 newly diagnosed metastatic lung adenocarcinoma patients with the EGFR 19Del, L858R mutation from June 2016 to October 2018 were retrospectively analyzed. Total remission rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and patient 1-year/2-year survival between EGFR-TKIs combined with first-line platinum-containing double-drug chemotherapy (Observation) group and an EGFR-TKIs alone (Control) group were evaluated and analyzed. For lung adenocarcinoma patients with the EGFR 19Del, L858R mutation, the Observation group had a better ORR (81.4% vs 52.2%), mPFS (12.0 vs 9 months), and 2-year survival (72.1% vs 52.2%) than the Control group, and the differences were statistically significant (P < .05), but DCR (95.3% vs 88.1%) and 1-year survival (90.7% vs 83.6%) were not significantly different between the groups (P > .05). For lung adenocarcinoma with the EGFR 19Del mutation, the Observation group showed a better ORR (81.8% vs 54.3%), and mPFS (14.5 vs 11.0 months) than the Control group, and the differences were statistically significant (P < .05), but DCR (95.5% vs 91.4%), 1-year survival (90.9% vs 85.7%), and 2-year survival (72.7% vs 60.0%) were not significantly different (P > .05). For lung adenocarcinoma with the EGFR L858R mutation, the Observation group showed a better ORR (81.0% vs 50.0%), mPFS (12.0 vs 9.0 months), and 2-year survival (71.4% vs 43.8%) than the Control group (P < .05), but DCR (95.2% vs 84.4%) and 1-year survival (90.5% vs 81.3%) were not significantly different (P > .05). Compared to EGFR-TKIs alone, EGFR-TKIs combined with chemotherapy improved ORR and mPFS in cases of advanced lung adenocarcinoma with EGFR 19Del, L858R mutation. In particular, patients with the EGFR L858R mutation showed a long-term survival benefit trend. EGFR-TKIs combined chemotherapy may therefore be a viable treatment method for delaying targeted drug resistance.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000034110</identifier><identifier>PMID: 37390279</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Adenocarcinoma of Lung - drug therapy ; Adenocarcinoma of Lung - genetics ; Cohort Studies ; ErbB Receptors - genetics ; Exons - genetics ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Mutation ; Observational Study ; Prognosis ; Retrospective Studies ; Tyrosine Kinase Inhibitors - therapeutic use</subject><ispartof>Medicine (Baltimore), 2023-06, Vol.102 (26), p.e34110-e34110</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4011-1f35ef0a2c86c12127fa8660219cdbaed254629ae35f92de13ad02c5097df6d13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313250/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313250/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,862,883,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37390279$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhou, Jinhua</creatorcontrib><creatorcontrib>Qin, Hongya</creatorcontrib><creatorcontrib>Miao, Jianlong</creatorcontrib><creatorcontrib>Liu, Ruijuan</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><title>Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>The aim of this study was to investigate the clinical efficacy and determine the prognostic value of Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) alone versus EGFR-TKIs plus chemotherapy for the treatment of advanced lung adenocarcinoma with EGFR Exon 19 Deletion(19Del), Exon 21 L858R (L858R) mutation. The demographic and clinical characteristics of 110 newly diagnosed metastatic lung adenocarcinoma patients with the EGFR 19Del, L858R mutation from June 2016 to October 2018 were retrospectively analyzed. Total remission rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and patient 1-year/2-year survival between EGFR-TKIs combined with first-line platinum-containing double-drug chemotherapy (Observation) group and an EGFR-TKIs alone (Control) group were evaluated and analyzed. For lung adenocarcinoma patients with the EGFR 19Del, L858R mutation, the Observation group had a better ORR (81.4% vs 52.2%), mPFS (12.0 vs 9 months), and 2-year survival (72.1% vs 52.2%) than the Control group, and the differences were statistically significant (P < .05), but DCR (95.3% vs 88.1%) and 1-year survival (90.7% vs 83.6%) were not significantly different between the groups (P > .05). For lung adenocarcinoma with the EGFR 19Del mutation, the Observation group showed a better ORR (81.8% vs 54.3%), and mPFS (14.5 vs 11.0 months) than the Control group, and the differences were statistically significant (P < .05), but DCR (95.5% vs 91.4%), 1-year survival (90.9% vs 85.7%), and 2-year survival (72.7% vs 60.0%) were not significantly different (P > .05). For lung adenocarcinoma with the EGFR L858R mutation, the Observation group showed a better ORR (81.0% vs 50.0%), mPFS (12.0 vs 9.0 months), and 2-year survival (71.4% vs 43.8%) than the Control group (P < .05), but DCR (95.2% vs 84.4%) and 1-year survival (90.5% vs 81.3%) were not significantly different (P > .05). Compared to EGFR-TKIs alone, EGFR-TKIs combined with chemotherapy improved ORR and mPFS in cases of advanced lung adenocarcinoma with EGFR 19Del, L858R mutation. In particular, patients with the EGFR L858R mutation showed a long-term survival benefit trend. EGFR-TKIs combined chemotherapy may therefore be a viable treatment method for delaying targeted drug resistance.</description><subject>Adenocarcinoma of Lung - drug therapy</subject><subject>Adenocarcinoma of Lung - genetics</subject><subject>Cohort Studies</subject><subject>ErbB Receptors - genetics</subject><subject>Exons - genetics</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Mutation</subject><subject>Observational Study</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Tyrosine Kinase Inhibitors - therapeutic use</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUttuEzEQXSEQDYUvQEJ-5IEtvuwl5gVVTVoqUiFV5dly7NmswWsH25uQr-SXcJJSCn4Zz_GZM0eeKYrXBJ8RzNv3N7Mz_PewihD8pJiQmjVlzZvqaTHBmNZly9vqpHgR4zeMCWtp9bw4YS3jmLZ8Uvyad51RUu2QX0YIG5mMd0g6jdbBr5yPJuZM2t3-4js0v7q8Le8-X2fUegdoAyGO8RG8tjlVPQw-9RDkeodM1tMb6RRoZEe3yhk4r2RQxvlBoq1J_UEAzX_m3oSjGVjY-3h3RChBi2k9vUXDmA7-PqBz1JuYfMjWLVK-9yGhmEa9e1k866SN8Oo-nhZfL-d3F5_KxZer64vzRakqTEhJOlZDhyVV00YRSmjbyWnTYEq40ksJmtZVQ7kEVnecaiBMakxVnf9dd40m7LT4eNRdj8sBtAKXgrRiHcwgw054acS_L870YuU3gmBGGK1xVnh7rxD8jxFiEoOJCqyVDvwYBZ1mWttw2mYqO1JV8DEG6B76ECz2uyBuZuL_XchVbx5bfKj5M_xMqI6Erbcpz_G7HbcQRA_Spv6gV7eclhRThhuGcblHCPsN3fPBEA</recordid><startdate>20230630</startdate><enddate>20230630</enddate><creator>Zhou, Jinhua</creator><creator>Qin, Hongya</creator><creator>Miao, Jianlong</creator><creator>Liu, Ruijuan</creator><creator>Wang, Wei</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230630</creationdate><title>Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study</title><author>Zhou, Jinhua ; Qin, Hongya ; Miao, Jianlong ; Liu, Ruijuan ; Wang, Wei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4011-1f35ef0a2c86c12127fa8660219cdbaed254629ae35f92de13ad02c5097df6d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adenocarcinoma of Lung - drug therapy</topic><topic>Adenocarcinoma of Lung - genetics</topic><topic>Cohort Studies</topic><topic>ErbB Receptors - genetics</topic><topic>Exons - genetics</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Mutation</topic><topic>Observational Study</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Tyrosine Kinase Inhibitors - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Jinhua</creatorcontrib><creatorcontrib>Qin, Hongya</creatorcontrib><creatorcontrib>Miao, Jianlong</creatorcontrib><creatorcontrib>Liu, Ruijuan</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Jinhua</au><au>Qin, Hongya</au><au>Miao, Jianlong</au><au>Liu, Ruijuan</au><au>Wang, Wei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2023-06-30</date><risdate>2023</risdate><volume>102</volume><issue>26</issue><spage>e34110</spage><epage>e34110</epage><pages>e34110-e34110</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>The aim of this study was to investigate the clinical efficacy and determine the prognostic value of Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) alone versus EGFR-TKIs plus chemotherapy for the treatment of advanced lung adenocarcinoma with EGFR Exon 19 Deletion(19Del), Exon 21 L858R (L858R) mutation. The demographic and clinical characteristics of 110 newly diagnosed metastatic lung adenocarcinoma patients with the EGFR 19Del, L858R mutation from June 2016 to October 2018 were retrospectively analyzed. Total remission rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and patient 1-year/2-year survival between EGFR-TKIs combined with first-line platinum-containing double-drug chemotherapy (Observation) group and an EGFR-TKIs alone (Control) group were evaluated and analyzed. For lung adenocarcinoma patients with the EGFR 19Del, L858R mutation, the Observation group had a better ORR (81.4% vs 52.2%), mPFS (12.0 vs 9 months), and 2-year survival (72.1% vs 52.2%) than the Control group, and the differences were statistically significant (P < .05), but DCR (95.3% vs 88.1%) and 1-year survival (90.7% vs 83.6%) were not significantly different between the groups (P > .05). For lung adenocarcinoma with the EGFR 19Del mutation, the Observation group showed a better ORR (81.8% vs 54.3%), and mPFS (14.5 vs 11.0 months) than the Control group, and the differences were statistically significant (P < .05), but DCR (95.5% vs 91.4%), 1-year survival (90.9% vs 85.7%), and 2-year survival (72.7% vs 60.0%) were not significantly different (P > .05). For lung adenocarcinoma with the EGFR L858R mutation, the Observation group showed a better ORR (81.0% vs 50.0%), mPFS (12.0 vs 9.0 months), and 2-year survival (71.4% vs 43.8%) than the Control group (P < .05), but DCR (95.2% vs 84.4%) and 1-year survival (90.5% vs 81.3%) were not significantly different (P > .05). Compared to EGFR-TKIs alone, EGFR-TKIs combined with chemotherapy improved ORR and mPFS in cases of advanced lung adenocarcinoma with EGFR 19Del, L858R mutation. In particular, patients with the EGFR L858R mutation showed a long-term survival benefit trend. EGFR-TKIs combined chemotherapy may therefore be a viable treatment method for delaying targeted drug resistance.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>37390279</pmid><doi>10.1097/MD.0000000000034110</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2023-06, Vol.102 (26), p.e34110-e34110 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10313250 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adenocarcinoma of Lung - drug therapy Adenocarcinoma of Lung - genetics Cohort Studies ErbB Receptors - genetics Exons - genetics Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mutation Observational Study Prognosis Retrospective Studies Tyrosine Kinase Inhibitors - therapeutic use |
| title | Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T01%3A36%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20observation%20and%20prognosis%20analysis%20of%20EGFR-TKIs%20alone%20versus%20EGFR-TKIs%20plus%20chemotherapy%20in%20advanced%20lung%20adenocarcinoma%20with%20EGFR%20Exon%2019%20Deletion,%20Exon%2021%20L858R%20mutation:%20A%20historical%20cohort%20study&rft.jtitle=Medicine%20(Baltimore)&rft.au=Zhou,%20Jinhua&rft.date=2023-06-30&rft.volume=102&rft.issue=26&rft.spage=e34110&rft.epage=e34110&rft.pages=e34110-e34110&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000034110&rft_dat=%3Cproquest_pubme%3E2832576927%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2832576927&rft_id=info:pmid/37390279&rfr_iscdi=true |